Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
Dr. Shakardokht Jafari named 2024 Innovator of the Year at Dynamic Awards in Brighton's Grand Hotel.
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
Graduate secures vital government backing for innovative cancer treatment, targeting global markets with Sirius Programme.
Dr. Shakar Jafari recognized by Business Leader magazine among UK's inspiring entrepreneurs, highlighting entrepreneurial journey and innovation.
